Latest News and Press Releases

The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Thursday April 3, 2025 at 4:00 pm CEST at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the...

Please read the announcement in PDF Attachment 2025_10_Share_buyback_program ...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

The employees  have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives (in alphabetical order after...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

On March 5, 2025, Novonesis will initiate a share buyback program as announced in Company Announcement No. 3 of February 26, 2025. Under the program, Novonesis will buy back B shares worth up to EUR...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

The Executive Leadership Team members eligible for the Novozymes A/S 2022-2024 incentive program has on February 26, 2025, received the allocated shares. An overview of the number and value of shares...

Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of...

2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%. 2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin.    2024 organic pro...